Local Consolidative Therapy After Dual Immunotherapy Fizzles in Metastatic NSCLC

Local Consolidative Therapy After Dual Immunotherapy Fizzles in Metastatic NSCLC

(MedPage Today) -- Local consolidative therapy (LCT) after induction treatment with nivolumab (Opdivo) plus ipilimumab (Yervoy) failed to improve survival outcomes in patients with metastatic non-small cell lung cancer (NSCLC), including those...

MD Anderson trial challenges local consolidative therapy paradigm in NSCLC

Adding local consolidative therapy (LCT) after induction treatment with nivolumab plus ipilimumab did not improve overall survival or progression-free survival in patients with metastatic non-small cell lung cancer (NSCLC), including those with oligometastatic disease, according to results presented at the International Association for the Study of Lung Cancer (IASLC) 2026 World Conference on Lung Cancer (WCLC).

Local consolidative therapy does not improve survival after dual immunotherapy in metastatic NSCLC

Adding local consolidative therapy (LCT) after induction treatment with nivolumab plus ipilimumab did not improve overall survival or progression-free survival in patients with metastatic non-small cell lung cancer (NSCLC), including those with oligometastatic disease, according to results presented at the International Association for the Study of Lung Cancer (IASLC) 2026 World Conference on Lung Cancer (WCLC).

LCT Fails to Improve Survival in Metastatic NSCLC After Nivolumab/Ipilimumab Failure - Archyworldys

Local consolidative therapy (LCT) following induction with nivolumab and ipilimumab fails to improve overall or progression-free survival in patients with metastatic non-small cell lung cancer (NSCLC), according to phase 3 data from the LONESTAR trial presented at the International Association for the Study of Lung Cancer (IASLC) 2026 World Conference on Lung Cancer in Seoul. ...